ArticleBlood2014

Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy.

Jennifer A Woyach et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.